Silexion Therapeutics announces successful completion of toxicology studies for SIL204, their next-generation RNA silencing therapy targeting mutated KRAS oncogenes.
Positive preclinical data demonstrates significant inhibition of cancer cell growth and anti-tumor activity in pancreatic cancer sites.
Toxicology studies confirm safety of SIL204 with no systemic organ toxicity, paving the way for Phase 2/3 clinical trial in locally advanced pancreatic cancer.
Successful Completion of Toxicology Studies
Confirms safety of SIL204 with no systemic organ toxicity.
Advancement Towards Regulatory Submissions
Company progressing towards regulatory submissions to Israel and Germany.
Initiation of Phase 2/3 Clinical Trial
On track to start the trial in Q2 2026 for locally advanced pancreatic cancer.
Innovative RNA Silencing Therapy
SIL204 designed for enhanced delivery, stability, and antitumor activity.
- Results from toxicology studies support planned timelines for Phase 2/3 trial initiation.
- SIL204's potential efficacy in treating aggressive cancers is bolstered by positive preclinical evidence.
- Integrated treatment regimen approach shows promise for improving survival in patients with mutated KRAS oncogene-driven cancers.
Silexion Therapeutics remains focused on advancing innovative treatments for solid tumor cancers with mutated KRAS oncogenes, aiming to improve patient outcomes and survival rates. The upcoming Phase 2/3 clinical trial in LAPC marks a significant milestone in their mission to bring SIL204 to patients in need of effective cancer treatments.